Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
6 reports, 4 independent
Updated Oct 11
Gone quiet
- Reports
- 6
- Developments
- 2
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Bio-Techne shares traded on Nasdaq, and TD Cowen reiterated a Buy rating with a $65 price target.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.William Blair and TD Cowen downgraded Bio-Techne stock ratings.1 source
TD Cowen reiterated a Buy rating and $65 price target for Bio-Techne shares traded on Nasdaq.1 source
Keep exploring
The entities involved
-
Bio-Techne
company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
- Ongoing conflict in the Middle East is causing energy shocks, driving policy decisions, and leading to market exuberance affecting companies like Nvidia and those listed on Nasdaq.
- Global investor interest in India is growing, driven by the country's economic growth and attracting international companies.
-
TD Cowen
American investment bank
Related events
- TD Cowen boosted its price target and gave a buy rating for Jazz Pharmaceuticals.
- TD Cowen and Bank of America issued buy ratings and increased price targets on November 2, 2026.
- TD Cowen lowered its price target for Beauty Health, while Invesco and Rhumbline increased their holdings in the stock.
- TD Cowen reiterated its buy rating on ExlService Holdings, Inc. shares.
- TD Cowen and Scotiabank provided ratings and price targets for Devon Energy.